Acrivon Therapeutics, Common Stock Investor Sentiment

ACRV Stock   7.58  0.06  0.80%   
Slightly above 53% of Acrivon Therapeutics,'s investor base is interested to short. The analysis of the overall investor sentiment regarding Acrivon Therapeutics, Common suggests that many traders are impartial. Acrivon Therapeutics,'s investing sentiment can be driven by a variety of factors including economic data, Acrivon Therapeutics,'s earnings reports, geopolitical events, and overall market trends.
  

Acrivon Therapeutics, Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Acrivon Therapeutics, can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over a year ago at news.google.com         
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq ... - Marketscreener.com
Google News at Macroaxis
over a year ago at benzinga.com         
Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference
benzinga news
over a year ago at finance.yahoo.com         
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635
Yahoo News
over a year ago at thelincolnianonline.com         
Acrivon Therapeutics, Inc. Receives 22.88 Average Price Target from Brokerages
news
over a year ago at www.macroaxis.com         
Payment of 239023 shares by Blumejensen Peter of Acrivon Therapeutics subject to Rule 16b-3
Macroaxis News
over a year ago at www.macroaxis.com         
Payment of 1470 shares by Rasmus HolmJorgensen of Acrivon Therapeutics subject to Rule 16b-3
Macroaxis News
over a year ago at thelincolnianonline.com         
Acrivon Therapeutics Price Target Lowered to 24.00 at BMO Capital Markets
news
over a year ago at news.google.com         
Form 10-Q Acrivon Therapeutics, For Sep 30 - StreetInsider.com
Google News at Macroaxis
over a year ago at seekingalpha.com         
Acrivon Therapeutics GAAP EPS of -0.66 beats by 0.04
seekingalpha News
over a year ago at globenewswire.com         
Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
Macroaxis News: globenewswire.com
over a year ago at thelincolnianonline.com         
Acrivon Therapeutics, Inc. Receives 23.00 Consensus Price Target from Analysts
news
over a year ago at www.macroaxis.com         
Payment of 2232 shares by Miller Mary of Acrivon Therapeutics subject to Rule 16b-3
Macroaxis News
over a year ago at finance.yahoo.com         
Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSi...
Yahoo News
over a year ago at finance.yahoo.com         
Acrivon Therapeutics Is In A Good Position To Deliver On Growth Plans
Yahoo News
over a year ago at thelincolnianonline.com         
Acrivon Therapeutics Research Coverage Started at Maxim Group
news
Far too much social signal, news, headlines, and media speculation about Acrivon Therapeutics, that are available to investors today. That information is available publicly through Acrivon media outlets and privately through word of mouth or via Acrivon internal channels. However, regardless of the origin, that massive amount of Acrivon data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Acrivon Therapeutics, news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Acrivon Therapeutics, relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Acrivon Therapeutics,'s headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Acrivon Therapeutics, alpha.

Acrivon Therapeutics, Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 284 shares by Miller Mary of Acrivon Therapeutics, at 6.98 subject to Rule 16b-3
10/01/2024
2
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Ac...
10/11/2024
3
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635
10/16/2024
4
Acrivon Therapeutics GAAP EPS of -0.59
11/13/2024
5
Acrivon stock retains Outperform as BMO cuts target due to minor cash adjustments
11/14/2024
6
Disposition of 19910 shares by Blume-jensen Peter of Acrivon Therapeutics, at 6.44 subject to Rule 16b-3
11/21/2024

Additional Tools for Acrivon Stock Analysis

When running Acrivon Therapeutics,'s price analysis, check to measure Acrivon Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics, is operating at the current time. Most of Acrivon Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics,'s price. Additionally, you may evaluate how the addition of Acrivon Therapeutics, to your portfolios can decrease your overall portfolio volatility.